344 related articles for article (PubMed ID: 27071340)
1. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Parlati F; Lee SJ; Aujay M; Suzuki E; Levitsky K; Lorens JB; Micklem DR; Ruurs P; Sylvain C; Lu Y; Shenk KD; Bennett MK
Blood; 2009 Oct; 114(16):3439-47. PubMed ID: 19671918
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
Stewart AK
Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Aujay M; Ngo HT; Azab AK; Azab F; Quang P; Maiso P; Runnels J; Anderson KC; Demo S; Ghobrial IM
Blood; 2010 May; 115(20):4051-60. PubMed ID: 20110419
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
McBride A; Klaus JO; Stockerl-Goldstein K
Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
[TBL] [Abstract][Full Text] [Related]
9. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
12. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
13. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
14. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
15. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
[TBL] [Abstract][Full Text] [Related]
16. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
17. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.
Jakubowiak AJ
Cancer Treat Rev; 2014 Jul; 40(6):781-90. PubMed ID: 24630735
[TBL] [Abstract][Full Text] [Related]
18. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
